Biolase, Inc. BIOLQ
0.00
0.00
NaN
as of 23 Sep
- Market cap
- $2.3M
- P/E
- 0.0×
Follow BIOLQ
Growth Flags
show if company had growth for consecutive years
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(1,620.81%) | (1,229.27%) | (3,157.50%) | 1,349.30% | |
| (102.66%) | (100.28%) | (102.98%) | (100.09%) | ||
ROIC |
(118.79%) | (136.15%) | (171.31%) | (109.48%) | |
Return on Tangible Assets |
(350.76%) | (454.12%) | 750.88% | 424.86% | |
Average Days of Receivables |
40.71 | 42.51 | 38.34 | 27.99 | |
Free Cash Flow per Share |
(11.91) | (0.82) | (0.34) | (0.36) | |
Free Cash Flow |
(15.22) | (14.72) | (11.47) | (13.14) | |
Capital Expenditures |
(1.13) | (0.34) | 0.07 | 0.29 | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(62.44%) | (69.53%) | (69.66%) | (91.93%) | |
Accounts Receivable Turnover |
8.68 | 9.00 | 8.73 | 11.63 | |
Accounts Payable Turnover |
5.47 | 5.16 | 5.23 | 5.93 | |
Inventory Turnover |
2.38 | 2.21 | 2.55 | 2.55 | |
Average Days of Payables |
68.24 | 55.88 | 64.90 | 36.30 | |
Days of Inventory on Hand |
128.64 | 128.16 | 128.87 | 119.38 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
12.21% | 11.76% | 11.64% | 10.69% | |
Selling, General and Administrative Expense of Revenue |
58.29% | 57.66% | 57.20% | 53.11% | |
Share Based Compensation of Revenue |
3.42% | 3.95% | 3.42% | 2.46% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.37 | 0.38 | 0.32 | 0.41 | |
Depreciation/Fixed assets |
0.58 | 0.77 | 0.70 | 0.84 | |
Capex/Depreciation |
(0.35) | (0.09) | 0.02 | 0.09 | |
Revenue per Share |
38.47 | 2.74 | 1.38 | 1.28 | |
Operating CF per Share |
(11.03) | (0.81) | (0.35) | (0.37) | |
Capex per Share |
(0.88) | (0.02) | 0.00 | 0.01 | |
Capex to Sales |
0.02 | 0.01 | 0.00 | (0.01) | |
Net Profit Margin |
(76.52%) | (78.35%) | (78.50%) | (71.75%) |
Columns are period end dates